Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /home/onemedpl/public_html/database/comp_profile_include.php on line 64
Biotech Specialty Pharma

Del Mar Pharmaceuticals

1727 West Broadway Suite 400
Vancouver, BC V6J4W6 Canada
Phone
Fax

Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /home/onemedpl/public_html/database/comp_profile_include.php on line 92
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Anti-cancer therapies in new, high-impact orphan cancer indications

Management CEO: Jeffrey Bacha, B.Sc., M.B.A.; CSO: Dennis M. Brown, Ph.D.; CFO: Scott Praill, C.A./C.P.A.

Click here for Financial Data
Keywords: Oncology, Immunology, Cancer, Glioblastoma, GBM, Orphan Drug, Small Molecule, Del Mar Pharmacuticals, DelMar

Comment


Updated: Oct. 21, 2018


Description

DelMar Pharma's mission is to build shareholder value by rapidly developing and commercializing proven anti-cancer therapies in new high-impact orphan cancer indications where patients have failed mod......view more

Products / Services

VAL-083: Phase II, GBM VAL-083: Hematologic malignancies VAL-083: NSLSC DMP-001: Pre-IND DMP-002: Pre-IND......view more

Market / Customers

Del Mar's key customers are physicians treating end-stage cancers covered by orphan drug designations and pharmaceutical companies marketing lung cancer chemotherapeutics.......view more


Competitors / Substitutes / Alternatives

Currently, there are no products approved for GBM following the failure of Avastin....view more

Strategy

Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100Ms in North America and potentially billions of dollars worldwide. T...view more

Revenue / Funding

DelMar Pharma completed at $10.5 million private placement in conjunction with a reverse take-over transaction in Q12013. The company currently has funding to support its drug development activities ...view more

Status

VAL-083 is currently approved for the treatment of CML and lung cancer in overseas markets. Del Mar Pharma has filed an IND with VAL-083 for a Phase I/II study in refractory GBM. Previous clinical r...view more

Analyst Coverage


Fatal error: Uncaught Error: Call to undefined function echostr_replace() in /home/onemedpl/public_html/database/comp_profile_include.php:787 Stack trace: #0 /home/onemedpl/public_html/database/comp_profile.php(87): include() #1 {main} thrown in /home/onemedpl/public_html/database/comp_profile_include.php on line 787